Intriguingly, GALNT6 loss did not differ significantly among early-stage cancers (stage I, 8.5%; stage II, 10.8%), whereas, among late-stage cancers, stage III cancers had a significantly higher rate of GALNT6 loss (20.0%) than stage IV cancers (3.3%). Here, GALNT6 is linked to cancer.